Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Cardiotoxicity × Immunomodulating Agents × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 2 Heart Diseases 1 Cardiotoxicity 1

Interventions

Echocardiography 10 Electrocardiography 5 Trastuzumab 4 Social Determinants of Health 2 Doxorubicin 2 Blood Specimen Collection 2 Antineoplastic Agents 2 Vascular Stiffness 1 Standard of Care 1 Resistance Training 1 Pulse Wave Analysis 1 Positron Emission Tomography Computed Tomography 1 Magnetic Resonance Spectroscopy 1 Immunomodulating Agents 1 Hematologic Tests 1 Gonadal Steroid Hormones 1 EGFR tyrosine kinase inhibitor 324674 1 Clinical Laboratory Techniques 1 Cisplatin 1 Chemoradiotherapy 1 Cardiography, Impedance 1 Anthracyclines 1 Amplified Fragment Length Polymorphism Analysis 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03530215 2023-04-13

EROCA

Groupe Hospitalier Pitie-Salpetriere

500,000 enrolled

Heart Diseases, Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡